Peripheral nerve stimulator use and vecuronium dosing in critically ill patients

Hospital Pharmacy

Volumn 31, Issue 11, 1996, Pages 1418-1424

  Davie, Bradley F ^a   Shalansky, Stephen J ^b,c   Ross, Betty ^c  

^a MSA General Hospital   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LIONS GATE HOSPITAL   (Canada)

Author keywords

peripheral nerve stimulator (PNS); vecuronium

Indexed keywords

VECURONIUM;

ADULT; AGED; AREFLEXIA; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INFUSION; MALE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOPATHY; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; PARALYSIS;

EID: 0029797789     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hansen-Flaschen J, Brazinsky S, Basile C, et al. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure - a national survey. JAMA. 1991; 266 2870-2875.
2. Klessig HT, Geiger HJ, Murray MJ, et al A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med. 1992;20: 1341-1345
3. Hudes E, Kwok L. Clinical use of peripheral nerve stimulators in anesthesia. Can J Anaesth. 1987,34:525-534.
4. Shalansky K, Shalansky S. Selection and monitoring of muscle relaxants during mechanical ventilation. Can J Hosp Pharm. 1992;45:47-52.
5. Kravitz M, Pace N. Management of the mechanically ventilated patient receiving pancuronium bromide Heart Lung. 1979;8. 81-85.
6. Isenstein D, Venner D, Duggan J Neuromuscular blockade in the intensive care unit. Chest. 1992;102:1258-1266.
7. Buck ML, Reed MD. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients. Clin Pharm. 1991;10:32-48.
8. Brull S, Ehrenwerth J, Silverman D. Stimulation with submaximal current for train-of-four monitoring. Anesthesiology. 1990, 72:629-632.
9. Nagashima H, Nguyen H, Conforti M, et al. A simple method for monitoring muscular relaxation during continuous infusion of vecuronium. Can J Anaesth. 1988;35: 134-138.
10. Davidson J. Neuromuscular blockade. Focus Crit Care. 1993;18:512-560.
11. Kupfer Y, Namba T, Kaldawi E, et al. Prolonged weakness after long-term infusion of vecuronium bromide. Ann Intern Med. 1992:484-486.
12. Darrah WC, Johnston JR, Mirakhur RK. Vecuronium infusions for prolonged muscle relaxation in the intensive care unit. Crit Care Med. 1989;17.1297-1300.
13. Partridge BL, Abrams JH, Bazemore C et al Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med. 1990;18:1177-1179.
14. Segredo V, Matthay MA, Sharma ML, et al. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology. 1990;72:566-570.
15. Ellender PJ. The use of neuromuscular blocking agents in ICU patients. Hosp Pharm. 1994,29:36-39,43-44.
16. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature Crit Care Med. 1994;22: 884-893.
17. Cockgroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41
18. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13: 818-827.
19. Jedeikin R, Dolgunski E, Kaplan R, et al. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anaesthesia. 1987;42:858-860.
20. Warner WA. Neuromuscular blockade associated with gentamicin therapy. J Am Med Assoc 1971;215:1153.
21. Toft P, Helbo-Hansen S Interaction of ketamine with atracurium Br J Anaesth. 1989;62:319-320
22. van Poorten JF, Dhasmana KM, Kuypers RSM, et al. Verapamil and reversal of vecuronium neuromuscular blockade. Anesth Analg. 1984:63:155-157.
23. Doll DC, Rosenberg H. Antagonism of neuromuscular blockage by theophylline. Anesth Analg. 1979;58:139-140.
24. Debaene B, Beaussier M, Meistelman C, et al Monitoring the onset of neuromuscular block at orbicularis oculi can predict good intubating conditions during atracurium-induced neuromuscular block. Anesth Analg. 1995;80:360-363.
25. Segredo V, Caldwell JE, Matthay MA et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med. 1992;327:524-528.
26. Griffin D, Fairman N, Coursin D, et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest. 1992; 102:510-514.
27. Segredo V, Shin Y-S, Sharma ML, et al. Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats. Anesthesiology. 1991;74:1052-1059.
28. Bencini AF, Scaf AHJ, Sohn YJ, et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg. 1986;65:245-251
29. Fahey MR, Morris RB, Miller RD, et al. Pharmacokinetics of ORG NC 45 (Norcuron) in patients with and without renal failure. Br J Anaesth. 1981;53:1049-1053.
30. Hunter JM, Jones RS, Utting JE. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. Br J Anaesth. 1984;56:941-951.
31. Upton RA, Nguyen T-L, Miller RD, et al Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats. Anesth Analg. 1982;61:313-316.
32. Waser PG, Wiederkehr H, Chang Sin-Ren A. Distribution and kinetics of 14C-vecuronium in rats and mice Br J Anaesth 1987; 59:1044-1051.
33. Bencini AF, Scaf AHJ, Agoston S, et al. Disposition of vecuronium bromide in the cat. Br J Anaesth. 1985;57:782-788.
34. Caldwell JE, Szenohradszky J, Segredo V, et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacerylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther. 1994;270:1216-1222.
35. D'Hollander A, Massaux F, Nevelsteen M, et al.Age-dependent dose-response relationship in ORG NC 45 in anaesthetized patients. Br J Anaesth. 1982;54.653-657.
36. Lien CA, Matteo RS, Ornstein E et al. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg. 1991; 73:39-42.
37. O'Hara DA, Fragen RJ, Shanks CA. The effects of age on the dose-response curves for vecuronium in adults. Anesthesiology. 1985;63:542-544,
38. Bell PF, Mirakhur RK, Clarke RSJ, et al. Dose-response studies of atracurium, vecuronium and pancuronium in the elderly. Anaesthesia. 1989;44:925-927.
39. Rupp SM, Castagnoli KP, Fisher DM, et al Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology. 1987;67.45-49.
40. Funk DI, Crul JF, Pol FM. Effects of changes in acid-base balance on neuromuscular blockade produced by ORG-NC 45. Acta Anaesth Scand. 1980;24:119-124.
41. Ono K, Ohta Y, Morita K, et al. The influence of respiratory-induced acid-base changes on the action of non-depolarizing muscle relaxants in rats. Anesthesiology. 1988;68.357-362.
42. Feldman SA Effect of changes in electrolytes, hydration and pH upon the reactions to muscle relaxants. Br J Anaesth. 1963,35:546-551.
43. Miller RD, Roderick LL. Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine. Br J Anaesth. 1978;50:541-544.
44. Fuchs-Buder T, Wilder-Smith OH, Borgeat A, et al. Interaction of magnesium sulphate with vecuronium-induced neuromuscular block. Br J Anaesth. 1995;74:405-409.
45. Frawley P, Butterworth JF. Do antiarrhythmic doses of magnesium potentiate vecuronium? Nurse Anesth. 1992;3:8-13
46. Gramstad L, Hysing ES. Effect of ionized calcium on the neuromuscular blocking actions of atracurium and vecuronium in the cat. Br J Anaesth. 1990;64:199-206.
47. Coursin DB, Klasek G, Goelzer SL. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg. 1989;69.518-521.
48. Martineau RJ, St.-Jean B, Kitts JB, et al. Cumulation and reversal with prolonged infusions of atracurium and vecuronium. Can J Anaesth. 1992;39:670-676.
49. Wright PMC, Hart P, Lau M, et al. Cumulative characteristics of atracurium and vecuronium. Anesthesiology. 1994; 81: 59-68.
50. Mirakhur RK, Ferres CJ, Pandit SK. Muscle relaxation with an infusion of vecuronium. Anesthesiology. 1984;61(abstract): A293.
51. Ali HH, Savarese JJ, Basta SJ, et al Evaluation of cumulative properties of three new non-depolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium. Br J Anaesth. 1983;55:107S-11S.
52. Buzello W, Noldge G Repetitive administration of pancuronium and vecuronium (Org NC 45, Norcuron) in patients undergoing long lasting operations. Br J Anaesth. 1982;54:1151-1157.
53. Crul JF, Booij LHDJ. First clinical experiences with ORG NC 45. Br J Anaesth. 1980;52:49S-51S.
54. Krieg N, Crul JE Booij LHDJ. Relative potency of ORG NC 45, pancuronium, alcuronium and tubocurarine in anaesthetized man. Br J Anaesth. 1980;52: 783-787.
55. Marshall IG, Agoston S, Booij LHDJ, et al. Pharmacology of ORG NC 45 compared with other non-depolarizing neuromuscular blocking drugs. Br J Anaesth. 1980;52: 11S-19S.
56. Schwartz AE, Matteo RS, Ornstein E, et al Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg. 1992;74:515-518.
57. Arden JR, Lynam DP, Castagnoli KP, et al Vecuronium in alcoholic liver disease: A pharmacokinetic and pharmacodynamic analysis. Anesthesiology. 1988;68:771-776
58. Hunter JM, Parker CJR, Bell CF, et al. The use of different doses of vecuronium in patients with liver dysfunction. Br J Anaesth. 1985;57:758-764.
59. Bell CF, Hunter JM, Jones RS, et al. Use of atracurium and vecuronium in patients with oesophogeal varices. Br J Anaesth. 1985;57:160-168.
60. Lebrault C, Berger JL, D'Hollander AA, et al. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology. 1985:62 601-605.